Stocks and Investing
Stocks and Investing
Thu, August 22, 2019
Wed, August 21, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, August 20, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Alethia Young Maintained (SRPT) at Buy with Decreased Target to $201 on, Aug 20th, 2019
Alethia Young of Credit Suisse, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $207 to $201 on, Aug 20th, 2019.
Alethia has made no other calls on SRPT in the last 4 months.
There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 0 agree with Alethia's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Alethia
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $220 on, Tuesday, July 9th, 2019
- Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $220 on, Monday, July 1st, 2019
- Joel Beatty of "Citigroup" Maintained at Strong Buy with Decreased Target to $190 on, Thursday, May 16th, 2019